Dayvigo Side Effects: Potentially Permanent Adverse Events Explained

What Are the Most Common Side Effects of Dayvigo?

Somnolence is the most frequently reported adverse event in lemborexant clinical trials, occurring in roughly 7% of patients on 5 mg and 10% on 10 mg, compared with about 1% on placebo. Other common effects include headache, dizziness, and fatigue. These side effects are generally dose-dependent and resolve with discontinuation.

Somnolence and Next-Day Impairment

The SUNRISE-1 randomized controlled trial (N=291) compared lemborexant 5 mg and 10 mg against placebo and zolpidem extended-release 6.25 mg over six months. Lemborexant 10 mg produced statistically significant improvements in sleep onset and maintenance, but participants also reported higher rates of somnolence relative to placebo [1]. The FDA label specifically notes that next-morning driving impairment has been documented in traffic simulation studies, with the 10 mg dose showing greater impairment than 5 mg [2].

Patients should not drive or operate heavy machinery the morning after taking Dayvigo until they feel fully awake. Even when subjective sleepiness resolves, objective psychomotor testing may still show residual impairment, a gap that can persist several hours longer than patients expect [2].

Headache and Dizziness

In SUNRISE-2 (N=949), headache was reported in approximately 6% of lemborexant-treated patients across the 5 mg and 10 mg groups versus 5% in the placebo arm, making it a modest but real risk [3]. Dizziness appeared at lower rates (roughly 2 to 3%) and was generally mild. Neither effect led to high rates of discontinuation in the trial population.

What Are the Rare Side Effects of Dayvigo?

Several low-frequency adverse events are documented in the FDA prescribing information and post-market reports. These include sleep paralysis, hypnagogic or hypnopompic hallucinations, cataplexy-like leg weakness, and complex sleep behaviors. Though rare, each deserves individual attention because the consequences can range from distressing to life-threatening.

Sleep Paralysis

Sleep paralysis, a transient inability to move or speak during sleep transitions, was reported in 1% to 2% of lemborexant-treated patients in controlled trials [2]. The mechanism ties directly to lemborexant's orexin blockade: orexin (hypocretin) normally stabilizes the boundary between wakefulness and REM sleep, and suppressing that signal can blur the line between states.

Episodes typically last seconds to a few minutes and resolve spontaneously. Patients who experience them repeatedly may develop anticipatory anxiety around bedtime, a psychological effect that can outlast the medication itself. Clinicians at HealthRX advise documenting the frequency and duration of any sleep paralysis episodes and reassessing whether the 10 mg dose should be stepped down to 5 mg.

Hypnagogic and Hypnopompic Hallucinations

Hallucinations occurring at sleep onset (hypnagogic) or on waking (hypnopompic) were reported in approximately 1% of patients in the SUNRISE program [2]. These vivid perceptual experiences can be frightening, and patients occasionally seek emergency care, misinterpreting them as signs of a psychiatric event.

The hallucinations are pharmacologically driven and typically cease after discontinuation. However, in a small subset of vulnerable patients, such as those with a personal or family history of psychosis or mood disorders, repeated hallucinatory episodes could theoretically reinforce maladaptive thought patterns. The FDA label cautions prescribers to use lemborexant carefully in patients with active psychiatric conditions [2].

Cataplexy-Like Symptoms

Transient episodes of leg weakness, resembling mild cataplexy, have been noted with dual orexin receptor antagonists as a class effect. The Dayvigo prescribing information lists this as an adverse reaction to watch for [2]. True cataplexy is a defining feature of narcolepsy type 1, and lemborexant is explicitly contraindicated in patients with narcolepsy because further orexin suppression could worsen their condition [2].

Complex Sleep Behaviors: The Black-Box Warning

The FDA placed a boxed warning on all orexin receptor antagonists, including lemborexant, after reports of complex sleep behaviors. These behaviors include sleepwalking, sleep driving, preparing and eating food, making phone calls, and having sex, all while not fully awake. Some patients have no memory of these events.

Why This Warning Exists

Post-market surveillance data submitted to the FDA FAERS database identified cases of serious injury and death associated with complex sleep behaviors during treatment with orexin receptor antagonists [2]. The FDA issued a Drug Safety Communication in 2019 requiring a boxed warning across this entire drug class [4]. Specific cases involved patients driving vehicles into other cars, falling from heights, and sustaining fractures.

In the SUNRISE trials, complex sleep behaviors were not common enough to generate a reliable incidence figure, but the severity of reported cases justified the strongest available label warning [2]. Even one unremembered episode of sleep driving represents a serious safety event.

Risk Factors That Increase Likelihood

Concomitant use of alcohol or central nervous system depressants significantly raises the risk of complex sleep behaviors. The prescribing information states that lemborexant should not be used with alcohol [2]. Patients taking benzodiazepines, gabapentinoids, antipsychotics, or other sedating agents are at higher baseline risk.

A personal history of prior complex sleep behaviors on any medication, including zolpidem, eszopiclone, or triazolam, is a clinical red flag. Clinicians should take a thorough medication and sleep history before initiating lemborexant at any dose [2].

When to Stop Immediately

The FDA label states explicitly: discontinue lemborexant immediately in any patient who reports a complex sleep behavior episode [2]. There is no threshold of acceptable frequency. A single confirmed event is sufficient grounds for permanent discontinuation. Patients should be counseled on this instruction before their first prescription is filled.

Potentially Permanent Side Effects: What the Evidence Shows

No adverse effect of lemborexant has been formally designated as irreversible in the Phase 3 clinical trial data. However, "not confirmed as permanent in a 12-month trial" does not mean "cannot be persistent." Several effects warrant careful consideration over longer time horizons.

Residual Cognitive and Psychomotor Impairment

Studies using simulated driving tasks showed that lemborexant 10 mg impairs driving performance the morning after a nighttime dose [2]. In a dedicated driving simulation study cited in the FDA review, the mean Standard Deviation of Lateral Position (SDLP), a validated measure of driving impairment, was significantly elevated at 9 hours post-dose for the 10 mg group [2].

The critical question is whether repeated nightly use produces cumulative cognitive effects. A review of orexin receptor antagonist pharmacology published in CNS Drugs noted that tolerance to sedation tends to develop over weeks, but the degree to which psychomotor recovery normalizes completely is not established for lemborexant specifically [5]. Patients who rely on precise reaction times for their work or safety, such as surgeons, pilots, or heavy machinery operators, should factor this into their risk-benefit calculation.

Psychological Dependence and Rebound Insomnia

Lemborexant's Schedule IV classification under the Controlled Substances Act reflects a recognized potential for misuse, abuse, and dependence [2]. In the SUNRISE-1 trial, sleep diary data collected after abrupt discontinuation showed no clinically meaningful rebound insomnia at doses of 5 mg or 10 mg, a favorable finding compared with some benzodiazepine hypnotics [1].

Yet individual patients may still experience subjective difficulty stopping. Psychological reliance on any sleep aid, where patients feel unable to sleep without it, can itself become a persistent problem. Cognitive behavioral therapy for insomnia (CBT-I) remains the first-line treatment endorsed by the American Academy of Sleep Medicine, and it is most effective when initiated alongside, rather than after, pharmacotherapy [6].

Rare Cases of Prolonged Neurological Effects

The FDA FAERS database, which collects voluntary spontaneous reports from patients and providers after a drug reaches the market, has received post-market reports of prolonged sleep disturbances, mood changes, and cognitive complaints following lemborexant use. These reports are not verified through controlled study and cannot establish causation, but they mirror similar spontaneous signals seen with suvorexant (Belsomra), the first approved DORA [7].

A 2021 pharmacovigilance analysis published in the Journal of Clinical Sleep Medicine examined FAERS reports for suvorexant and found cases of new-onset depression and anxiety persisting after discontinuation [8]. Lemborexant has not yet been the subject of an equivalent dedicated pharmacovigilance study given its more recent approval, but its shared mechanism means the same potential signal warrants monitoring.

Impact on REM Sleep Architecture

Lemborexant increases REM sleep duration and reduces the latency to REM onset [3]. This is an intended pharmacodynamic effect, since orexin suppression disinhibits REM-generating circuits. In short-term trials, this REM enhancement appears to improve sleep quality. Over longer periods, whether normalizing REM in patients with chronically disrupted sleep architecture leads to any durable downstream benefit or harm has not been established beyond the 12-month SUNRISE data [1][3].

Patients with pre-existing REM sleep behavior disorder (RBD), in which the normal muscle atonia of REM is absent, could theoretically experience amplified acting-out behaviors. The current prescribing information does not list RBD as a contraindication, but clinicians should screen for it before prescribing [2].

Dayvigo and Special Populations

Older Adults

SUNRISE-2 enrolled adults 65 years and older as a pre-specified subgroup. Older patients showed comparable efficacy but were more sensitive to somnolence and dizziness [3]. Falls are a major safety concern in this population: a single fall related to night-time somnolence or a complex sleep behavior event can result in a hip fracture, with mortality rates following hip fracture in adults over 80 reaching 20 to 30% within one year [9]. The FDA label recommends starting at 5 mg in older adults [2].

Patients With Hepatic Impairment

Lemborexant is extensively metabolized by CYP3A4. Mild hepatic impairment does not require dose adjustment, but moderate impairment limits the maximum recommended dose to 5 mg, and severe hepatic impairment is a contraindication [2]. CYP3A4 inhibitors such as fluconazole, clarithromycin, or ritonavir can substantially raise lemborexant plasma concentrations, increasing the risk of all dose-dependent side effects including the morning-after impairment described above.

Pregnancy and Lactation

Lemborexant has not been studied in pregnant or lactating humans. Animal reproductive toxicology data showed adverse developmental effects at doses exceeding the maximum recommended human dose [2]. The drug is not recommended during pregnancy. Lactating patients should consult their prescriber before continuing therapy.

How Dayvigo's Side Effect Profile Compares to Other Sleep Medications

Understanding lemborexant's risks in context helps clinicians and patients choose the most appropriate therapy.

Versus Zolpidem

SUNRISE-1 directly compared lemborexant against zolpidem extended-release 6.25 mg. Lemborexant 10 mg produced greater next-day somnolence rates than zolpidem in that trial, though zolpidem carries its own boxed warning for complex sleep behaviors [1][2]. Zolpidem's GABA-A mechanism also carries a higher physical dependence risk and withdrawal potential compared with lemborexant's orexin-based mechanism.

Versus Suvorexant (Belsomra)

Suvorexant, approved in 2014, shares lemborexant's DORA mechanism and its boxed warning [7]. A 2022 network meta-analysis in The Lancet compared multiple hypnotics and found lemborexant 10 mg statistically superior to suvorexant 20 mg on sleep onset latency improvement, though the absolute difference was modest [10]. Side effect profiles are broadly similar between the two DORAs, with somnolence and complex sleep behaviors as shared concerns.

Versus CBT-I

Cognitive behavioral therapy for insomnia achieves remission in 70 to 80% of patients and has no drug side effects [6]. The American College of Physicians recommends CBT-I as the initial treatment for chronic insomnia disorder in adults, with pharmacotherapy reserved for patients who do not respond to or cannot access behavioral treatment [11]. This recommendation applies directly to lemborexant prescribing decisions.

Monitoring and Risk Reduction in Clinical Practice

Prescribers can reduce the likelihood of serious adverse events through structured monitoring. Before starting lemborexant, a clinical sleep history should document any prior complex sleep behavior episodes, history of parasomnias, current CNS depressant use, and occupational requirements for morning alertness.

After initiation, patients should be reassessed at 30 days and 90 days to confirm the chosen dose is appropriate. If the 10 mg dose is selected, morning impairment should be explicitly asked about at each visit rather than assumed absent. Any report of amnesia, unusual behaviors, or perceived hallucinations warrants immediate reassessment of the benefit-risk balance.

The FDA label mandates that prescribers advise patients not to drive or engage in other hazardous activities after taking lemborexant if they have consumed alcohol that evening or have taken other CNS depressants [2]. This counseling point should be documented in the patient's record.

Patients aged 65 and older should begin at 5 mg, and a fall-risk screening tool such as the STEADI algorithm endorsed by the CDC should be applied at baseline and at follow-up visits [12].